Prima BioMed Ltd (ADR) (PBMD) was Initiated by Maxim Group to “Buy” and the brokerage firm has set the Price Target at $4. Maxim Group advised their investors in a research report released on Apr 19, 2016.
Prima BioMed Ltd (ADR) closed down -0.005 points or -0.55% at $0.91 with 1,42,637 shares getting traded on Monday. Post opening the session at $0.9, the shares hit an intraday low of $0.9 and an intraday high of $0.92 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company’s main pipeline of products is based on the LAG-3 immune control mechanism which plays a role in the regulation of the T cell immune response. The Company’s product is a T cell immunostimulatory factor (APC activator) IMP321 for cancer chemoimmunotherapy which has completed Phase II trials. In addition it has developed infrastructure for a cell-based therapy manufacturing platform and taken CVac an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. The Company’s other products include IMP731 for autoimmune disease and IMP701 for cancer and chronic infectious disease.